M

Medicofarma Biotech SA
WSE:MDB

Watchlist Manager
Medicofarma Biotech SA
WSE:MDB
Watchlist
Price: 0.36 PLN -9.55% Market Closed
Market Cap: 24.5m PLN
Have any thoughts about
Medicofarma Biotech SA?
Write Note

Medicofarma Biotech SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medicofarma Biotech SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
Medicofarma Biotech SA
WSE:MDB
Income from Continuing Operations
-zł2.7m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Income from Continuing Operations
-zł6.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-19%
R
Ryvu Therapeutics SA
WSE:RVU
Income from Continuing Operations
-zł104.1m
CAGR 3-Years
-13%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Income from Continuing Operations
zł47.4m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medicofarma Biotech SA
Glance View

Market Cap
24.5m PLN
Industry
Life Sciences Tools & Services

Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.

MDB Intrinsic Value
0.19 PLN
Overvaluation 46%
Intrinsic Value
Price
M

See Also

What is Medicofarma Biotech SA's Income from Continuing Operations?
Income from Continuing Operations
-2.7m PLN

Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Income from Continuing Operations amounts to -2.7m PLN.

What is Medicofarma Biotech SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-43%

Over the last year, the Income from Continuing Operations growth was -68%. The average annual Income from Continuing Operations growth rates for Medicofarma Biotech SA have been -43% over the past three years .

Back to Top